David John Webb

Christison Professor of Therapeutics and Clinical Pharmacology

University of Edinburgh

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David John Webb is the Christison Professor of Therapeutics and Clinical Pharmacology at the University of Edinburgh, UK. His research focuses on novel pharmacological approaches to managing hypertension, including the use of RNA-based therapeutics and health technology assessments for treatment efficiency. Recent articles highlight his work on the implications of siRNA targeting angiotensinogen in hypertension and the relationship between chronic kidney disease and cardiovascular health outcomes.

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (9)

Martin Feelisch

University of Southampton

UNITED KINGDOM

View details

Richard Weller

Reader

University of Edinburgh

UNITED KINGDOM

View details

Guest Professor

University Medical Center Hamburg-Eppendorf

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David John Webb

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Novel pharmacological approaches to lowering blood pressure and managing hypertension

Health technology assessment (HTA): Decisions on treatment efficiency guided by clinical judgement and pharmacoeconomics

Knowledge, attitudes, and practices related to hypertension among Sri Lankans: an online cross-sectional survey

Zilebesiran, a ribonucleic acid interference agent targeting angiotensinogen, proves a promising approach in hypertension

Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics

Choroidal and retinal thinning in chronic kidney disease independently associate with eGFR decline and are modifiable with treatment

Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension

Endothelin blockade prevents the long-term cardiovascular and renal sequelae of acute kidney injury in mice

The effect of daily UVA phototherapy for 2 weeks on clinic and 24-h blood pressure in individuals with mild hypertension

Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review

Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor‐Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen–Targeting Small Interfering RNA

Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial

Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease

Multi-layered Spatial Transcriptomics Identify Secretory Factors Promoting Human Hematopoietic Stem Cell Development

Chronotherapy in hypertension: the devil is in the details

Collaborators (9)

Martin Feelisch

Richard Weller

Neeraj Dhaun

Jessica Ivy

Peter Gallacher

Matthew Bailey

Kristina Kirschner

Robert Hunter

Pierre-Louis Tharaux

Make your next move.